Adaptive Biotechnologies Corporation (ADPT)
Last updated: 2026-10-21 16:39:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Adaptive Biotechnologies Corporation (ADPT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $25.33, with a market capitalization of $3.82B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.00 to $30.74. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$3.82B | |
$24.36 | |
$123.97 | |
$0.90 | |
$24.42 | |
859.06K | |
2.27M | |
-- | |
$30.74 | |
$12.00 | |
-- | |
-- |
Adaptive Biotechnologies Corporation (ADPT) Stock Price Today
Adaptive Biotechnologies Corporation (ADPT) is currently trading at $25.33 as of 2026-10-21 16:22:33, up 3.73% ($0.91) from the previous close of $24.42
During today's regular trading session, ADPT has traded between $0.90 and $123.97, with a trading volume of 859.06K shares. The current price is near the lower end of today's range.
Adaptive Biotechnologies Corporation (ADPT) 7-Day Stock Price Change
Over the past seven days, Adaptive Biotechnologies Corporation (ADPT) moved from $25.57 to $25.33, representing a decline of 0.93% ($0.24).
The stock traded between $23.85 and $26.49 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.87 million shares, down versus the previous seven-day period, indicating lower trading activity.
ADPT 52-Week Price Position
Position in Range: 71.1%
ADPT is currently trading at $25.33, placing it 71.1% of the way from its 52-week low of $12.00 to its 52-week high of $30.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Adaptive Biotechnologies Corporation (ADPT)?
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Adaptive Biotechnologies Corporation Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 624 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Adaptive Biotechnologies Corporation (ADPT) Stock on MEXC
Eligible investors can buy real shares of Adaptive Biotechnologies Corporation (ADPT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Adaptive Biotechnologies Corporation (ADPT) stock price today?
2.Is ADPT stock going up or down today?
3.What is ADPT pre-market price?
4.What is ADPT after-hours price?
5.Is ADPT stock trading now?
6.Where does ADPT sit relative to its 52-week high and low?
7.What sector is Adaptive Biotechnologies Corporation in?
8.What is Adaptive Biotechnologies Corporation's market capitalization and where is it listed?
9.How is ADPT valued in terms of P/E ratio and EPS?
10.Does Adaptive Biotechnologies Corporation pay a dividend?
Explore More US Stocks
Search Stocks
ADPT Stock Calculator
Estimate the value between ADPT shares and USD.
ADPT Shares to USD
1.00 ADPT shares = 25.331 USD
Calculations are estimates based on the latest available price and are for reference only.


